One of the great aspirations of gene therapy is to eventually develop technology which will provide a feasible approach to correct genetic defects and combat infectious diseases. My laboratory is engaged in studying the molecular biology of the defective human parvovirus adeno- addressed virus (AAV) in hopes of developing a safe efficient viral vector for human gene therapy. AAV is a dependent parvovirus. That is, it requires coinfection with another virus (either adenovirus or certain members of the herpes virus group) in order to undergo a productive infection in cultured cells. In a lytic infection, AAV DNA replicates as a 4.7 kilobase double-stranded molecule and is packaged into virion as linear single strands of both polarities. In the absence of coinfection with helper virus, the AAV genome integrates via its ends into the host genome in a site specific manner and resides there in a latent state until the cell is infected with helper virus. Then the AAV DNA is """"""""rescued"""""""", replicates and establishes a normal productive infection. AAV has a broad host range for infectivity (human, monkey, mouse, etc.) when coinfected with the appropriate helper. In fact, compared to the current retroviral vectors these features of AAV are of considerable interest in utilizing AAV as a viral vector. Human AAV has a number of advantages. Some of them are: (1) it is ubiquitous in humans, (2) AAV can be concentrated to titers exceeding 10(9) infectious units per milliliter, and (3) it is completely nonpathogenic integrating virus. Ongoing research is revealing that this nonpathogenic human virus is now accessible for utilization as a vector. We have developed a packaging system which allows for efficient encapsidation of foreign genes into AAV virions. We have also identified the essential cis-acting sequences required for efficient integration into host cell DNA. Finally, we have characterized wild type integration and uncovered the exciting result of site-specific integration. This last observation clearly sets apart AAV as a eucaryotic viral vector and it's potential for gene therapy in humans. The overall objective of the proposed work is to fully test the feasibility of AAV as a specific transducing viral vector for globin gene therapy.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
7R01HL048347-03
Application #
3367506
Study Section
Special Emphasis Panel (SRC (FJ))
Project Start
1992-04-01
Project End
1997-01-31
Budget Start
1993-09-20
Budget End
1994-01-31
Support Year
3
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Chao, H; Monahan, P E; Liu, Y et al. (2001) Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther 4:217-22
Young Jr, S M; Samulski, R J (2001) Adeno-associated virus (AAV) site-specific recombination does not require a Rep-dependent origin of replication within the AAV terminal repeat. Proc Natl Acad Sci U S A 98:13525-30
McCarty, D M; Monahan, P E; Samulski, R J (2001) Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 8:1248-54
Gush, K A; Fu, K L; Grompe, M et al. (2000) Phenotypic correction of Fanconi anemia group C knockout mice. Blood 95:700-4
Chao, H; Liu, Y; Rabinowitz, J et al. (2000) Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2:619-23
Young Jr, S M; McCarty, D M; Degtyareva, N et al. (2000) Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination. J Virol 74:3953-66
Bartlett, J S; Wilcher, R; Samulski, R J (2000) Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol 74:2777-85
Gavin, D K; Young Jr, S M; Xiao, W et al. (1999) Charge-to-alanine mutagenesis of the adeno-associated virus type 2 Rep78/68 proteins yields temperature-sensitive and magnesium-dependent variants. J Virol 73:9433-45
Xiao, X; Li, J; Samulski, R J (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72:2224-32
Haberman, R P; McCown, T J; Samulski, R J (1998) Inducible long-term gene expression in brain with adeno-associated virus gene transfer. Gene Ther 5:1604-11

Showing the most recent 10 out of 19 publications